P111 - “no energy, zip”: a mixed methods comparison of functional decline during immunotherapy, targeted therapy, and/or chemotherapy in older adults with non-small cell lung cancer (nsclc)
Publication date: November 2019Source: Journal of Geriatric Oncology, Volume 10, Issue 6, Supplement 1Author(s): M.L. Wong, A.K. Smith, C. Miaskowski, V. Musinipally, H.J. Cohen, V. Lam, M. Mazor, C.J. Ursem, K. Loh, J.A. Cohen, D. Shumay, A.O. Levin, N. Dixit, J. Grandi, L.C. Walter
Purpose of review Recently, the combination of antiangiogenic agents, chemotherapy and immunotherapy has shown synergistic anticancer effects in non-small cell lung cancer (NSCLC). The future for this approach appears bright in lung cancer treatment; however, many challenges remain to be overcome regarding its true potential, optimal sequence and timing of therapy, and safety profile. In this review, we will discuss the current status and future direction of antiangiogenic therapy for the treatment of NSCLC, and highlight emerging strategies, such as tumor vessel normalization (TVN). Recent findings Bevacizumab was th...
In conclusion, solid data regarding the benefit of ICIs in ECOG PS2 NSCLC patients are currently lacking and the role of immunotherapy remains uncertain for PS2 patients. Prospective randomized trials addressing this question are warranted or ongoing. However, we are concerned that without a more extensive and objective assessment of patients ’ fitness and frailty by using and validating appropriate tools a clear answer may not come to light.
In conclusion, our study delineate a new mechanism used by lung cancer cells to inhibit NK cell’s anti-cancer activity through exosome delivery, and inspire further research into the clinical application of miR-150 inhibition for immunotherapy.
Conclusions: In our hospital, molecular diagnostic is performed in all patients with advanced NSCLC to customize therapy. This study, while showing our local experience, corroborates data obtained in the literature. Thus, despite the small sample size, this may be the basis for future studies and help improve clinical practice.
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Objective: Anti-PD-1 antibodies can cause drug-induced pneumonitis. We aimed to identify the clinical and radiologic characteristics, the incidence, risk factors, and appropriate management of pneumonitis related to anti-PD-1 immunotherapy in patients with non-small cell lung cancer (NSCLC).Materials and Methods: Medical records and chest computed tomography scans of patients with NSCLC treated with anti-PD-1 antibodies between January 2016 and June 2018 at the Kanagawa Cancer Center were retrospectively analyzed. Clinical characteristics of patients treated with anti-PD-1 antibodies who developed pneumonitis were compared...
Conclusions: In this study we confirmed that ICI drugs can occasionally develop clearly defined autoimmune systemic diseases besides pulmonary toxicity. While discontinuation of therapy and/or treatment can result in resolution of irAEs, long-term sequelae and death have been reported. More studies are needed in order to develop more precise treatments for immunotherapy-related adverse events.
ConclusionThe confinement within the radiation field and the latency of appearance are suggestive of delayed radiation myelopathy. Nevertheless, the relatively low dose of radiation received and the full recovery after pembrolizumab discontinuation and steroid therapy plead for the contribution of both radiotherapy and immunotherapy in the causality of this complication, as an enhanced inflammatory reaction on a focal post-radiation chronic inflammatory state. In the three previously described cases of myelopathy occurring after radiotherapy and immunotherapy, a complete recovery had not been obtained and the immunotherapy...
Conclusions: In our exploratory study of stage III and IV NSCLC patients with CAO, addition of PDT demonstrated hazard of mortality comparable to radiation + chemotherapy group. However, addition of non-PDT ablation showed higher mortality compared to the radiation + chemotherapy group. Future studies should investigate the efficacy and effectiveness of multimodal therapy including radiation, chemo, immunotherapy and bronchoscopic interventions. PMID: 31737325 [PubMed]
Immunotherapy, Ahead of Print.